Back to Search
Start Over
Semiallogeneic Cancer Vaccines Formulated With Granulocyte-Macrophage Colony-Stimulating Factor for Patients With Metastatic Gastrointestinal Adenocarcinomas: A Pilot Phase I Study
- Source :
- Journal of Immunotherapy. 24:19-26
- Publication Year :
- 2001
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2001.
-
Abstract
- The authors report the results of a phase I clinical study using semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat patients with metastatic adenocarcinomas of the gastrointestinal tract. A specially engineered cell line, FO1-12, was used to generate semiallogeneic hybrids by fusion with patient-derived tumor cells; the hybrids express HLA class I and II haplotypes derived from both parental cells. For treatment, the vaccine was mixed with GM-CSF, irradiated, and injected intradermally into patients at weekly or biweekly intervals. Vaccinations were associated with minimal or no toxicity and showed that semiallogeneic hybrids formulated with GM-CSF can induce a specific antitumor immune response in some patients, as measured by a delayed-type hypersensitivity response to autologous tumor cells. Because of the simplicity, feasibility, and flexibility of this immunotherapeutic approach, semiallogeneic hybrid vaccines have the potential to be used in the treatment of virtually any type of cancer.
- Subjects :
- Adult
Male
Cancer Research
medicine.medical_treatment
Immunology
Pilot Projects
Human leukocyte antigen
Adenocarcinoma
Hybrid Cells
Cancer Vaccines
Immunotherapy, Adoptive
Immune system
Tumor Cells, Cultured
medicine
Humans
Immunology and Allergy
Aged
Gastrointestinal Neoplasms
Aged, 80 and over
Pharmacology
Vaccines, Synthetic
Gastrointestinal tract
business.industry
Granulocyte-Macrophage Colony-Stimulating Factor
Cancer
Immunotherapy
Middle Aged
medicine.disease
Vaccination
Granulocyte macrophage colony-stimulating factor
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 15249557
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- Journal of Immunotherapy
- Accession number :
- edsair.doi.dedup.....05d22e211e4b193ad39358ee2d6c04d9